1887

Abstract

strain J5 mutants of various origins have often been used as vaccines for induction of crossreactive, cross-protective antibodies directed against the lipopolysaccharide (LPS) core region. The antigenic composition of LPS from J5 strains of different origin, i.e. strains J5(U), J5(UK), J5(2877) and J5(a), was investigated using monoclonal antibodies (mAbs) reactive only with LPS of a given chemotype, i.e. one specific for the incomplete core of the Re chemotype, a second mAb reactive only with the R3 complete core, and a third specific for the O-antigen of serovar O111. The LPS of strains J5(U) and J5(a) is almost exclusively composed of LPS of the Re chemotype, LPS of the J5(UK) strain is composed of Rc LPS and R3 complete core, while LPS of the J5(2877) strain contains Rc, R3 complete core and O-antigen. Growth of the bacteria in medium supplemented with galactose led to increased expression of complete core. The immune responses to the various strains were investigated. Antiserum to the J5 strain expressing the largest amount of R3 core [J5(UK)] had much higher anti-R3 LPS antibody titres compared to antiserum to the other strains. mAb 53, representative of the anti-R3 response to J5 strains containing complete core, bound to those LPS expressing the R3 core. Thus, the R3 LPS, present in some J5 vaccine strains is at least partially responsible for some of the cross-reactivities exhibited by some anti-J5 antisera. The present findings may explain some of the discrepant outcomes reported for cross-protection studies with J5 antisera, where J5 strains of various origins grown under different culture conditions have been used as vaccines and where LPS or bacteria expressing various core types have been used for challenge.

Loading

Article metrics loading...

/content/journal/micro/10.1099/00221287-139-11-2641
1993-11-01
2022-01-24
Loading full text...

Full text loading...

/deliver/fulltext/micro/139/11/mic-139-11-2641.html?itemId=/content/journal/micro/10.1099/00221287-139-11-2641&mimeType=html&fmt=ahah

References

  1. Appelmelk B. J., Cohen J. 1992; The protective role of antibodies to the lipopolysaccharide core region. . In Bacterial Endotoxic Lipopolysaccharides 2 Immunopharmacology and Pathophysiology pp. 375–410 Ryan J. L., Morrison D. C. Edited by Boca Raton: CRC Press;
    [Google Scholar]
  2. Appelmelk B. J., Rapson N. T., Verweij-Van Vught A. M. J. J., Maaskant J. J., Hekker T. A. M., Peerbooms P. G. H., Maclaren D. M., Thijs L. G. 1986; Heterogeneity of Escherichia coli J5 vaccines. Lancet ii:1273–1274
    [Google Scholar]
  3. Appelmelk B. J., Verweij-Van Vught A. M. J. J., Maaskant J. J., Schouten W. F., Dejong A. J. R., Thijis L. G., Maclaren D. M. 1988; Production and characterization of mouse monoclonal antibodies reacting with the lipopolysaccharide core region of Gramnegative bacilli. Journal of Medical Microbiology 26:107–114
    [Google Scholar]
  4. Aydintung M. K., Inzana T. J., Letonja T., Davis W. C., Corbeil L. B. 1989; Cross-reactivity of monoclonal antibodies to Escherichia coli with heterologous Gram-negative bacteria and extracted lipopolysaccharides. Journal of Infectious Diseases 160:846–857
    [Google Scholar]
  5. Elbein A. D., Heath E. C. 1965; The biosynthesis of cell wall lipopolysaccharide in Escherichia coli. I. The biochemical properties of a uridine diphosphate galactose 4-epimeraseless mutant. Journal of Biological Chemistry 240:1919–1925
    [Google Scholar]
  6. Evans M. E., Pollack M., Koles N. L., Hardegen N. J., Panopoulos D. 1992; Lipopolysaccharide heterogeneity in Escherichia coli J5 variants: analysis by flow cytometry. Journal of Infectious Diseases 166:803–811
    [Google Scholar]
  7. Galanos C., Lüderitz O., Westphal O. 1969; A new method for the extraction of R lipopolysaccharides. European Journal of Biochemistry 9:245–249
    [Google Scholar]
  8. Gibb A. P., Barclay G. R., Poxton I. R., Dipadova F. 1992; Frequencies of lipopolysaccharide core types among clinical isolates of Escherichia coli defined with monoclonal antibodies. Journal of Infectious Diseases 166:1051–1057
    [Google Scholar]
  9. Holst O., Brade H. 1992; Chemical structure OF the core region of lipopolysaccharides. In Bacterial Endotoxic Lipopolysaccharides 1 Molecular Biochemistry and Cellular Biology pp. 135–170 Ryan J. L., Morrison D. C. Edited by Boca Raton: CRC Press;
    [Google Scholar]
  10. Kaca W., De Jongh-Leuvenink J., Zahringer U., Rietschel E. T., Brade H., Verhoef J., Sinwell V. 1988; Isolation of 7–O–(2-amino-2-deoxy-α-d-glucopyranosyl)-l-glycero-d-manno-heptose as a constituent of the lipopolysaccharide of the UDP-galactose epimerase-less mutant J-5 ofEscherichia coliandVibrio cholerae.. Carbohydrate Research 179:289–299
    [Google Scholar]
  11. Pollack M., Chia J. K. S., Koles N. L., Miller M., Guelde G. 1989; Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A region of bacterial lipopolysaccharide. Journal of Infectious Diseases 159:168–188
    [Google Scholar]
  12. Schmidt G., Fromme I., Mayer H. 1970; Immunochemical studies on core lipopolysaccharides of Enterobacteriaceae of different genera. European Journal of Biochemistry 14:357–366
    [Google Scholar]
  13. Tsai C. M., Frasch C. E. 1982; A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Analytical Biochemistry 119:115–119
    [Google Scholar]
  14. Westphal O., Jann K. 1965; Bacterial lipopolysaccharides. Extraction with phenol-water and further applications of the procedure. Methods in Carbohydrate Chemistry 5:83–91
    [Google Scholar]
  15. Ziegler E. J., Douglas H., Sherman J. E., Davis C. E., Braude A. I. 1973; Treatment of E. coli and Klebsiella bacteremia in agranylocytic animals with antiserum to a UDP-Gal epimerase-deficient mutant. Journal of Immunology 111:433–438
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/00221287-139-11-2641
Loading
/content/journal/micro/10.1099/00221287-139-11-2641
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error